RGD Reference Report - Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.

Authors: Kung, AL  Rebel, VI  Bronson, RT  Ch'ng, LE  Sieff, CA  Livingston, DM  Yao, TP 
Citation: Kung AL, etal., Genes Dev 2000 Feb 1;14(3):272-7.
RGD ID: 734820
Pubmed: PMID:10673499   (View Abstract at PubMed)
PMCID: PMC316359   (View Article at PubMed Central)

Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Rubinstein-Taybi syndrome  ISOCrebbp (Mus musculus)734820; 734820 RGD 
Rubinstein-Taybi syndrome  IAGP 734820 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Crebbp  (CREB binding protein)

Genes (Mus musculus)
Crebbp  (CREB binding protein)

Genes (Homo sapiens)
CREBBP  (CREB binding protein)

Objects referenced in this article
Gene Ep300 E1A binding protein p300 Mus musculus
Gene Kat2b K(lysine) acetyltransferase 2B Mus musculus

Additional Information